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Abstract
Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV) is a rare and lethal disorder mainly involving the
vascular development of the lungs. Since its first description, significant achievements in research have led to a better understanding
of the underlying molecular mechanism of ACD/MPV and genetic studies have identified associations with genomic alterations in
the locus of the transcription factor FOXF1. This in turn has increased the awareness among clinicians resulting in over 200 cases
reported so far, including genotyping of patients in most recent reports. Collectively, this promoted a better stratification of the
patient group, leading to new perspectives in research on the pathogenesis. Here, we provide an overview of the clinical aspects of
ACD/MPV, including guidance for clinicians, and review the ongoing research into the complex molecular mechanism causing this
severe lung disorder.
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Clinical presentation
The clinical presentation of alveolar capillary dysplasia with
misalignment of the pulmonary veins (ACD/MPV) is char-
acterized by respiratory distress and cyanosis caused by
severe pulmonary hypertension (PH) and insufficient
oxygen uptake.1–3 Ninety-five percent of ACD/MPV
patients are born at full term with normal birth weights
and Apgar scores4,5 and most patients develop symptoms
within the first 24 h of life.1,6,7 In up to 80% of the cases,
associated malformations are found for which surgery is
occasionally needed.3,8–14 These malformations predomin-
antly affect the gastrointestinal tract, but also affect the car-
diovascular and urogenital system.2–5,9,15,16 Irrespective of
the co-morbidities, the mortality of ACD/MPV is almost
100%. The vast majority succumb to hypoxemic respiratory
failure within days to weeks after presentation despite
receiving supportive care including extracorporeal
membrane oxygenation (ECMO).4,12,17–24 Atypical, milder
cases of ACD/MPV patients that present after 24 h of life or
survive beyond the neonatal period have sporadically been
described and will be discussed in the histology section.
Incidence
Since ACD/MPV was first described in 1981, over 200 cases
have been reported.3,25 In 2000, Al-Hathlol et al. reported
two ACD/MPV patients among 226 infants autopsied over
a 10-year period in the province of Manitoba, Canada.4
During these 10 years, the total number of deliveries was
170,000, with 340 infants dying within the neonatal period.
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It is unclear whether other ACD/MPV cases were among the
remaining deceased neonates because an autopsy or biopsy is
needed for confirmation. Based on this study, the incidence
can be estimated at approximately 1/100,000. In The
Netherlands, the incidence can be estimated at 1/200,000 if
calculated from the total number of ACD/MPV patients (20)
diagnosed in either the Radboudumc Amalia Children’s
Hospital Nijmegen or the Sophia Children’s Hospital
Rotterdam since 1993 and the total number of living births
during this period (4.3 million26). However, also in The
Netherlands, it is likely that ACD/MPV is underdiagnosed
and sometimesmisdiagnosed as idiopathic PH due to the lack
of autopsies.
Diagnosis
The current gold standard to unambiguously diagnose ACD/
MPV is histological examination of the lungs. In the majority
of studies, most cases were diagnosed postmortem by aut-
opsy.4,5,27 In one study, 85% of cases were diagnosed premor-
tem by open lung biopsy.1 In this study, the median time from
admission to lung biopsy was 6.5 days. Of neonatal patients
who underwent an open lung biopsy during ECMO therapy in
the Sophia Children’s Hospital Rotterdam or the
Radboudumc Amalia Children’s Hospital Nijmegen, 32%
were diagnosed with ACD/MPV. In all these patients, treat-
ment was withdrawn due to futility. In order to avoid unneces-
sary and expensive ECMO treatment, it is recommended to
perform a lung biopsy before starting ECMO therapy or, if it
has been initiated already, within the first week of ECMO.28
Considering the non-uniformly distribution of lung involve-
ment observed in some patients, it is recommended to obtain
more than one lung sample to avoid false-negatives.
Echocardiography is used to confirm PH and to exclude
structural cardiovascular abnormalities.1,4,7,10,18,19,21,29 An
X-ray of the lungs does not show features specific for
ACD/MPV, but can show unspecific diffuse haziness or
pneumothoraces, most likely caused by mechanical ventila-
tion.4,7,10,18,19,29 A computed tomography (CT) scan may
show bilateral widespread ground-glass infiltrates with
septal line thickening,12,21 while a CT angiography does
not result in the diagnosis either due to the limitations of
imaging most peripheral capillaries of the lung.
Photoacoustic imaging, however, is able to perform molecu-
lar imaging at a high resolution inside different tissues and
therefore overcomes the limitations of a CT angiography.
So far, photoacoustic imaging has only been used in bio-
medical research settings, but since studies in humans are
very promising, it could provide an excellent tool to diag-
nose ACD/MPV in the future.30
During pregnancy, there are no clinical signs associated
with ACD/MPV. However, if there is a high suspicion for
ACD/MPV, for instance after an earlier familial case, fetal
genetic testing for deletions and mutations in the FOXF1
locus could contribute to an early diagnosis.16,31 In addition,
a decreased total fetal lung volume (FLV) measured by
prenatal magnetic resonance imaging (MRI) and ultrasound
together with a lowered MRI signal intensity can be used to
detect fetal pulmonary hypoplasia associated with multiple
diffuse lung developmental disorders among others, includ-
ing ACD/MPV.32 An early detection of ACD/MPV allows
adequate prenatal counseling regarding the dismal progno-
sis although the postnatal clinical course must be observed
as it differs between patients. Histological examination will
be necessary to confirm the diagnosis.
Histology
On gross examination, the lungs in cases of ACD/MPV
appear bulky with up to a threefold increase in expected
weight due to increased interstitial tissue.33–35 The most sig-
nificant differences between ACD/MPV and healthy lungs are
noted on a microscopic level. In normal lungs, the alveolar
capillaries are in close contact with the alveolar epithelium
lined by flattened type 1 pneumocytes to provide sufficient
gas exchange. In cases of ACD/MPV, the lung tissue is char-
acterized by diffuse thickening of interalveolar septa and
marked reduction of pulmonary alveolar capillaries. In add-
ition, these scanty alveolar capillaries are located away from
the alveolar epithelium which is predominantly composed of
hyperplastic cuboidal type 2 pneumocytes (Fig. 1a).3–5,33–35
Typically, in cases of ACD/MPV, the walls of small periph-
eral pulmonary arteries are thickened due to hypertrophic
smooth muscle cells in the media (Fig. 1b). Further, the
majority of ACD/MPV patients present with peripheral
veins in the bronchovascular bundle adjacent to the pulmon-
ary arteries outside the interlobular septa while normally they
are located within the septa. This phenomenon is called ‘‘mis-
alignment of the pulmonary veins’’ (Fig. 1c).
It is postulated that the milder phenotype of atypical
ACD/MPV patients, including late presenters and long-
term survivors, is correlated with the extent of affected
lung tissue.12,19–21,24,36 Although a few atypical patients
with diffuse histological findings similar to the typical
patients have been described,18,22 a very recent study
showed a heterogeneous non-uniform distribution of histo-
logical findings in all atypical ACD/MPV patients.36
Nevertheless, correlating the histological features with pheno-
typical differences between patients remains difficult due to
factors such as incomplete autopsy records, varying co-exist-
ing malformations, and variations in treatment, especially
concerning treatment withdrawal.5 Either way, when a
biopsy is obtained to confirm the diagnosis of ACD/MPV,
consideration should be given to the possibility of uneven
distribution of lesions. This is especially important if no
other life-threatening co-malformations are found and the
prognosis is based solely on the severity of lung lesions.
Treatment
Similar to persistent PH of the newborn (PPHN), the clin-
ical approach to ACD/MPV consists of general supportive
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cardiorespiratory care and vasodilatory agents to reduce
PH. In most cases, intubation and mechanical ventilation
are immediately required at time of presentation due to
the very low oxygen saturation levels. Rarely, only supple-
mental oxygen is temporarily enough to stabilize the patient
before mechanical ventilation is needed.4,7,10,15,17,20,37 To
reduce the pulmonary vascular resistance, inhaled nitric
oxide and oral or intravenous vasodilatory agents such as
milrinone, sildenafil, or epoprostenol are used. In the short
term, this can improve the saturation levels, but literature
shows that the dosage needs to be increased repeatedly and
that eventually the severe hypoxemia will be
fatal.4,5,7,10,18,20,22,23,37,38 Interestingly, one atypical ACD/
MPV patient was still alive on oral vasodilators and supple-
mental oxygen at the age of 38 months when the case report
was written.21
ECMO therapy can be used to stabilize infants in life-
threatening conditions if the diagnosis is not clear. Yet, the
vast majority of ACD/MPV patients cannot be weaned
from ECMO, while ECMO itself is invasive, comes with
risks of complications, and is expensive.1,4,7,8,19,23,28,29,37
Ideally, an open lung biopsy is performed before ECMO
therapy has started or at least before a ‘‘second-run’’
ECMO therapy is considered.7,14,27,28 On the other hand,
ECMO therapy can provide an excellent bridge to lung
transplantation in ACD/MPV patients with a mild pheno-
type.12,36 To date, seven ACD/MPV patients receiving bilat-
eral lung transplantation have been reported in the United
States with a comparable five-year survival (56%) to infants
transplanted for other indications at the St. Louis Children’s
Hospital, Missouri.36,39 All of the transplanted ACD/MPV
patients had an atypical milder phenotype than the classical
ACD/MPV patients.12,36,40 Although the overall survival in
this young age group is still disappointing, ECMO therapy
followed by lung transplantation is the potential treatment
of choice for selected ACD/MPV patients.36,41–43
Pathogenesis
Although the pathogenesis of ACD/MPV has not yet been
fully defined, several hypotheses implicating various factors
and events have been proposed. It is thought that ACD/
MPV is caused by an early disturbance in embryonic lung
development. Already at the end of the embryonic phase of
lung development (five weeks of gestation), the two lung
buds are surrounded by a vascular network that is con-
nected to the systemic circulation. During the pseudogland-
ular phase (5–16 weeks of gestation), this network expands
by angiogenesis when the two buds branch into the loose
mesenchymal tissue. In the canalicular and saccular stage
(16–26 and 26–38 weeks of gestation, respectively), expan-
sion of the network continues, increasing the capillary dens-
ity in the developing lung.44,45 The deficiency of capillaries
in ACD/MPV lung tissue implies a disturbance already in
the early embryonic and pseudoglandular phase. The pres-
ence of thickened septa and simplified acini with a reduced
number of type 1 pneumocytes in ACD/MPV lungs indicate
that also the saccular stage is affected, in which normally the
alveolar saccules are formed with thin septa covered by type
1 pneumocytes.35,46,47
The cause of PH in ACD/MPV is still a topic of discus-
sion. It was suggested that chronic hypoxemia in the new-
born induces hypertrophic arterial changes which cause
PH.35,38 However, this seems unlikely because the extent
of arterial changes in ACD/MPV newborns would imply
Fig. 1. Lung histology of a 2-week-old infant with ACD/MPV. (a)
Immunostaining for CD31 (brown color) highlighting a reduced number
of alveolar capillary endothelial cells located away (arrows) from the
inner side of the alveoli (dashed lines) in ACD/MPV compared to con-
trol lung. (b) Illustration of a hypertrophic arterial wall (*) in hematoxylin
and eosin stained lung tissue from an ACD/MPV case compared to
control. (c) Illustration of the misaligned pulmonary veins (V) adjacent
to the bronchiole (B) and thickened pulmonary arteriole (A) in tri-
chrome stained ACD/MPV lung tissue. Magnifications: (a) 200; (b)
50; (c) 100.
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the presence of hypoxemia already during early fetal life
when the oxygen is still provided by the placenta.
Moreover, this theory is inconsistent with the poor outcome
of ACD/MPV patients despite mechanical ventilation or
ECMO therapy which diminishes the hypoxemia. Another,
more acceptable, theory is that the PH results from a
marked reduction in the alveolar capillary bed.18,33
However, abrupt deterioration in late presenters without
any signs of PH during the time before deterioration ques-
tions this theory as well.4,18,23,33,34 Collectively, the progres-
sive PH combined with structural histological changes in all
ACD/MPV patients suggests a disturbance in normal pul-
monary vascular development and is currently the subject of
several studies in different laboratories.
The origin of the ‘‘misaligned pulmonary veins’’ found in
peripheral ACD/MPV lung tissue, and whether they are
indeed malpositioned, is not clear. Considering the presence
of valves, it is more likely that the anomalous veins originate
from bronchial veins that normally do not extend beyond
the larger bronchopulmonary branches.33–35 This theory is
supported by a study showing ‘‘misaligned pulmonary
veins’’ originating from bronchial veins and act as shunt
vessels between the bronchial and pulmonary veins.48
Role of FOXF1 in ACD/MPV
In 2009, Stanckiewizc and Shaw-Smith suggested an associ-
ation between ACD/MPV and haploinsufficiency of the
Forkhead Box F1 (FOXF1) gene.2 Since then, they have
accumulated the largest ACD/MPV sample collection of
141 patients in which they identified 86 pathogenic variants
containing copy number variations (CNVs), point muta-
tions, and one complex rearrangement, all involving the
FOXF1 gene or its regulatory region.49 This regulatory
region was identified by defining the shortest region of over-
lapping genomic deletions in ACD/MPV patients.50,51 The
remaining 55 cases were not genetically tested due to insuf-
ficient DNA quality.49 Additionally, a variety of heterozy-
gous genomic variants in the FOXF1 locus of ACD/MPV
patients have been reported by other research groups.8,16,20
Most of the variants are collected in the Leiden Open
Variation Database (LOVD).52
FOXF1, first described by Pierrou et al. in 1994, is a
member of the Forkhead box transcription factors (TFs)
and plays a role during embryonic development, specifically
in lung development.53 Studies in rodent embryos show that
FOXF1 is already expressed at the primitive streak stage in
the mesodermal lateral plate and continues to be expressed
during development in mesenchymal lung tissue.54–58 Very
little is known about FOXF1 expression during human lung
development, but in newborns FOXF1 is expressed in mes-
enchymal stromal cells from tracheal aspirates.59 FOXF1 is
regulated by Sonic hedgehog (SHH) signaling, one of the
key regulators of embryonic development.60 Further
research on the signaling pathways involving FOXF1 is
ongoing. A recent study showed that the serotonin
transporter (SERT) protein, important during pulmonary
vascular remodeling and adaptation at birth, might be one
of the downstream targets of FOXF1 as the expression of
SERT protein was completely absent in ACD/MPV patients
while expression levels in other disorders causing PH in the
newborn were normal.61 Although rodent models enable us
to study the function of FOXF1 during lung development,
the phenotype of heterozygous FoxF1 mice does not com-
pletely correlate with ACD/MPV. Similar to ACD/MPV,
heterozygous deletion of FoxF1 gives rise to multiple foregut
and lung defects including lobular and alveolar underdevel-
opment, compact lung mesenchyme, and hemorrhagic
lesions. However, the pulmonary branching defects domin-
ate in these models while the main problem in ACD/MPV is
the underdeveloped pulmonary vascularization.62 These dif-
ferences illustrate the difficulties of studying the pathogen-
esis of ACD/MPV.
Imprinting of FOXF1
The question why a heterozygous genomic alteration in the
FOXF1 gene or its regulatory region causes haploinsuffi-
ciency and results in ACD/MPV is still unanswered. The
most suggested and studied explanation is parental imprint-
ing where epigenetic marks determine if a particular gene is
only expressed on the paternal or maternal allele.2,50,54,63
Assuming this hypothesis is true, all genomic alterations
associated with ACD/MPV would be located on the same
parental chromosome. Indeed, all but one of the deletions
located in the regulatory region did arise on the maternal
chromosome. However, mutations located in the FOXF1
transcription region are found on both paternal and mater-
nal alleles. Still, this might implicate parental imprinting of
the regulatory region instead of the transcription region
itself.49 Unfortunately, detailed studies on imprinting of
the FOXF1 locus in fetal, neonatal, and adult lung tissue
have not been able to confirm this idea.50,64
Phenotypical differences of ACD/MPV
Although earlier studies suggested a high correlation
between ACD/MPV and genomic alterations in the
FOXF1 locus, familial cases show large phenotypical differ-
ences and, again, illustrate the complexity of the molecular
mechanisms causing ACD/MPV. In total, eight ACD/MPV
families with associated genomic variants in the FOXF1
transcription region have been reported so far (Fig. 2;
Table 1).49,63,65,66 In six of these families, the pathogenic
variant was also found in one of the parents including two
fathers who were mosaic. None of those parents exhibited
signs of ACD/MPV. The phenotypical variance is also illu-
strated by family 6 (Fig. 2) that was previously described by
Reiter et al.66 In this family, two children were affected by
ACD/MPV but only one of them showed classical features
of ACD/MPV. The other child presented with an atypical
form and survived. Interestingly, another sister carried the
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Fig. 2. Pedigrees of published ACD/MPV families corresponding to Table 1, illustrating the complex inheritance pattern. Filled square or
circle¼ affected male or female; open square or circle¼ unaffected male or female; crossed out¼ deceased; open triangle¼ spontaneous
abortion; crossed-out filled triangle¼ terminated pregnancy. /þ, presence of heterozygous variant in the FOXF1 gene; /, no variant in
FOXF1 gene present; P, variant located on paternal allele; M, variant located on maternal allele.
Table 1. Overview of published ACD/MPV families with genomic alterations in the FOXF1 gene.
Family number
(Fig. 2)
Genomic alteration
(all located in first
FOXF1 exon) Protein change Inheritance Parental inheritance Reference
1 c.416G>T Arg139Leu Maternal De novo paternal allele Sen et al., 2013
2 c.253T>A Phe85Ile Not found in parental
DNA: germline
mosaicism?
— Sen et al., 2013
3 Insertion 5
UTR side
Unknown Paternal De novo maternal allele Szafranski et al., 2016
4 c.849_850del p.Ile285fs Not found in parental
DNA: maternal
germline mosaicism?
— Szafranski et al., 2016
5 c90_96del p.Ser31fs Paternal; 20% mosaicism in
blood nucleated cells
De novo, allele unknown Szafranski et al., 2016
6 c.231C>A p.Phe77Leu Paternal; 70% mosaicism in
blood nucleated cells
De novo paternal allele Reiter et al., 2016
7 c.253T>C p.Phe85Leu Maternal Unknown Sen et al., 2013
8 c.294C>A p.His98Gln Maternal Unknown Sen et al., 2013
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same mutation but was unaffected.49,66 The genotype–
phenotype variation might be associated with altered
FOXF1 expression levels, similar to FoxF1 heterozygote
knock-out mice that show variation in the phenotype sever-
ity correlated to FoxF1 expression levels.58 Different expres-
sion levels can be the result of so-called ‘‘modifier genes’’
that modify the expression of the FOXF1 gene. In combin-
ation with mutations or deletions in the FOXF1 locus, alter-
ations in these modifier genes might lead to ACD/MPV.
This idea is supported by the finding that the survival of
heterozygous FoxF1 knock-out mice depends on their gen-
etic background.62
Summary
ACD/MPV is a rare, almost uniformly lethal, developmen-
tal disorder of the lungs. Patients suffer from severe hypox-
emia and PH that progresses over time. Although the
awareness of ACD/MPV is growing among clinicians, it
can be confused with idiopathic PH as the clinical picture
is similar. This prolongs the time to confirm the diagnosis
and contributes to unnecessary suffering of patients and a
high cost of therapy. As soon as the response to medical
treatment deviates from the expected, a histological exam-
ination should be performed. Moreover, an open lung
biopsy is ideally performed before ECMO therapy or surgi-
cal interventions for co-occurring anomalies are initiated.
For a very small selection of atypical ACD/MPV patients,
a lung transplantation can be considered although survival
rates are still disappointing. ACD/MPV is associated with
haploinsufficiency of FOXF1, a TF regulated by SHH that
plays a significant role during early lung development.
Although phenotypical differences are present, prenatal or
postnatal genetic testing could contribute to earlier detec-
tion and allows adequate consultation about the prognosis
and the process of decision-making.
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